DIREVO to collaborate with MedImmune on therapeutic protease for the treatment of CNS diseases
Under the terms of the agreement, Direvo will be applying its proprietary protein-engineering capabilities to create specifically engineered proteases. MedImmune will then be responsible for the development and marketing of the protease product that may arise under the agreement. Direvo will receive undisclosed upfront and milestone payments, as well as research funding plus royalties on potential sales of the therapeutic protease should it reach the market.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.